These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22543346)

  • 21. Pharmacological treatment of hypercortisolism.
    Shalet S; Mukherjee A
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):234-8. PubMed ID: 18438170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Normocortisolemic Cushing's syndrome initially presenting with increased glucocorticoid receptor numbers.
    Newfield RS; Kalaitzoglou G; Licholai T; Chilton D; Ashraf J; Thompson EB; New MI
    J Clin Endocrinol Metab; 2000 Jan; 85(1):14-21. PubMed ID: 10634357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The medical management of Cushing's syndrome.
    Morris D; Grossman A
    Ann N Y Acad Sci; 2002 Sep; 970():119-33. PubMed ID: 12381547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamic pituitary MRI has high sensitivity and specificity for the diagnosis of mild Cushing's syndrome and should be part of the initial workup.
    Friedman TC; Zuckerbraun E; Lee ML; Kabil MS; Shahinian H
    Horm Metab Res; 2007 Jun; 39(6):451-6. PubMed ID: 17578763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FKBP5 mRNA Expression Is a Biomarker for GR Antagonism.
    Bali U; Phillips T; Hunt H; Unitt J
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4305-4312. PubMed ID: 27459525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
    Gross C; Blasey CM; Roe RL; Belanoff JK
    Obesity (Silver Spring); 2010 Dec; 18(12):2295-300. PubMed ID: 20339369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation and treatment of Cushing's syndrome.
    Nieman LK; Ilias I
    Am J Med; 2005 Dec; 118(12):1340-6. PubMed ID: 16378774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mifepristone (RU 486) for Alzheimer's disease.
    Pomara N; Doraiswamy PM; Tun H; Ferris S
    Neurology; 2002 May; 58(9):1436. PubMed ID: 12011303
    [No Abstract]   [Full Text] [Related]  

  • 30. Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy.
    Magiakou MA; Mastorakos G; Oldfield EH; Gomez MT; Doppman JL; Cutler GB; Nieman LK; Chrousos GP
    N Engl J Med; 1994 Sep; 331(10):629-36. PubMed ID: 8052272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia.
    Newfield RS; Spitz IM; Isacson C; New MI
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):399-404. PubMed ID: 11298094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mifepristone: is there a place in the treatment of Cushing's disease?
    Carmichael JD; Fleseriu M
    Endocrine; 2013 Aug; 44(1):20-32. PubMed ID: 23192246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease.
    van Aken MO; Pereira AM; van den Berg G; Romijn JA; Veldhuis JD; Roelfsema F
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):765-72. PubMed ID: 15163342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486.
    Nieman LK; Chrousos GP; Kellner C; Spitz IM; Nisula BC; Cutler GB; Merriam GR; Bardin CW; Loriaux DL
    J Clin Endocrinol Metab; 1985 Sep; 61(3):536-40. PubMed ID: 2991327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states.
    Pecori Giraldi F; Pivonello R; Ambrogio AG; De Martino MC; De Martin M; Scacchi M; Colao A; Toja PM; Lombardi G; Cavagnini F
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):251-7. PubMed ID: 17223996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of the treatment of Cushing's syndrome using ketoconazole].
    Conget JI; Halperin I; Vendrell J; Ferrer J; Martínez-Osaba MJ; Esmatjes E; Vilardell E
    Med Clin (Barc); 1989 Nov; 93(14):531-4. PubMed ID: 2695699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Personality characteristics and quality of life in patients treated for Cushing's syndrome.
    Sonino N; Bonnini S; Fallo F; Boscaro M; Fava GA
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):314-8. PubMed ID: 16487442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological management of Cushing's syndrome: an update.
    Dang CN; Trainer P
    Arq Bras Endocrinol Metabol; 2007 Nov; 51(8):1339-48. PubMed ID: 18209872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing's syndrome: a review of the Mayo Clinic experience.
    Chow JT; Thompson GB; Grant CS; Farley DR; Richards ML; Young WF
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):513-9. PubMed ID: 17970770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood pressure responses to phenylephrine infusions in subjects with Cushing's syndrome.
    McKnight JA; Rooney DP; Whitehead H; Atkinson AB
    J Hum Hypertens; 1995 Oct; 9(10):855-8. PubMed ID: 8576903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.